Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVES study of brigatinib for ALK-positive advanced non-small cell lung cancer with brain metastases
jRCTs071230025Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Takeda. Primary endpoint: Response rate in brain metastases. Started Nov 2023; status: active, not recruiting.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on jRCTs071230025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230025.